TP53 and cancer: An examination of cancer cell death in response to cisplatin and/or Oligo-Fucoidan confirmed that combined treatment further promoted the cleaved PARP (Asp214) and active caspase 3 levels compared with monotherapies (Figure 4C, lane eight vs. lanes six and seven), particularly in the p53+/+ context.